Table 4. . Cost–effectiveness results from the Medicare scenario analysis.
Atezolizumab | BSC | Incremental atezolizumab vs BSC | ICER | |
---|---|---|---|---|
Total cost ($) | 276,479 | 229,097 | 47,382 | 48,512/QALY |
QALYs | 6.302 | 5.325 | 0.977 |
BSC: Best supportive care; ICER: Incremental cost–effectiveness ratio; QALY: Quality-adjusted life-year.